Inloggad som:
ESPAC-6
Är du som patient intresserad av mer information om en studie, kontakta din behandlande läkare.
ESPAC-6
open labelled phase III adjuvant trial of disease-free survival in patients with resected pancreatic ductal adenocarcinoma randomized to allocation of oxaliplatin- or gemcitabine-based chemotherapy by standard clinical criteria or by a transcriptomic treatment specific stratification signature
open labelled phase III adjuvant trial of disease-free survival in patients with resected pancreatic ductal adenocarcinoma randomized to allocation of oxaliplatin- or gemcitabine-based chemotherapy by standard clinical criteria or by a transcriptomic treatment specific stratification signature
PLACEHOLDER
Att studera och försöka hitta nya biomarkörer som gör det möjligt att upptäcka och diagnostisera sjukdomen tidigare än vad vi gör idag.
Mer information om studien för vårdgivare
Histologically proven pancreatic ductal adenocarcinoma including variants, and acinar cell carcinoma. Patient had provided tumour tissue at resection for RNAseq. Macroscopically complete resection (R0 or R1 resection). Female and male Patients aged from 18 to 79 years. WHO performance status 0-1.
Other types of non-ductal tumour of the pancreas, including endocrine tumours or acinar cell
adenocarcinoma, cystadenocarcinoma, bile duct carcinoma, and ampullary carcinoma. Distant metastases, including ascites or malignant pleural effusion. Macroscopic incomplete tumour removal (R2 resection).
Behandling
Fas 3
Ej tillämpbar
Akademisk
Studien ändrades senast av: Akademiska sjukhus (2024-09-12)